Measurements of ECP in serum and the impact of plasma coagulation

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 55, Issue 5, 2000, Pages 442-448

  Björk, Anne ^a,b   Venge, P ^a   Peterson, C G B ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Allergy; Asthma; Eosinophil; Eosinophil cationic protein (ECP); Plasma coagulation; Serum measurements

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; CALCIUM; EDETIC ACID; EOSINOPHIL CATIONIC PROTEIN;

ALLERGY; ARTICLE; ASSAY; ASTHMA; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; EOSINOPHIL; HUMAN; MEDIATOR RELEASE; PLASMA; PRIORITY JOURNAL; SERUM; STORAGE; TEMPERATURE DEPENDENCE;

ASTHMA; BLOOD COAGULATION TESTS; BLOOD PROTEINS; CALCIUM; COCULTURE TECHNIQUES; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; GRANULOCYTES; HUMANS; HYPERSENSITIVITY; INFLAMMATION MEDIATORS; RIBONUCLEASES; SPECIMEN HANDLING; STATISTICS, NONPARAMETRIC; TEMPERATURE;

EID: 0034111621     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2000.00272.x     Document Type: Article

References (23)

1. 1. PETERSON CGB, JÔRNVALI H, VENGE P. Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol 1988;40:415-423.
2. 2. PETERSON CGB, ENANDER I, NYSTRAND J, ANDERSON AS, NILSSON L, VENGE P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vitro. Clin Exp Allergy 1991;21:561-567.
3. 3. FREDENS K, DAHL R, VENGE P. In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 1991;46:27-29.
4. 4. VENGE P. Human eosinophil granule proteins: structure, function and release. In: SMITH H, COOK RM, editors. Immunopharmacology of eosinophils. San Diego, CA: Academic Press, 1993:43-55.
5. 5. VENGE P, DAHL R, PETERSON C. Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effects of anti-asthmatic medication. Int Arch Allergy Appl Immunol 1988;87:306-312.
6. 6. GRIFFIN E, HÁKANSSON L, FORMGREN H, JORGENSEN KJ, PETERSON C, VENGE P. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J Allergy Clin Immunol 1991;87:548-557.
7. 7. TOMASSINI M, ADRIANI E, MAGRINI L, et al. Markers of eosinophilic inflammation in allergic diseases. Allergy 1993;48:133-137.
8. 8. MOTOJIMA S, FUKUDA T, MAKINO S, TAKATSU K. Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy 1993;48:98-106.
9. 9. HALLGREN R, VENGE P. The eosinophil in inflammation. In: Mattsson P, Ahlsledt S, Venge P, Thorell J, editors. Clinical impact of the monitoring of allergic inflammation. San Diego, CA: Academic Press, 1991:119-140.
10. 10. DAHL R, VENGE P, OLSSON I. Variations of blood eosinophils and eosinophilic cationic protein in serum in patients with bronchial asthma. Allergy 1978;33:211-215.
11. 11. SCHMEKEL B, VENGE P. Markers for eosinophils and T-lymphocytes as predictors of late asthmatic response. Allergy 1993;48:94-97.
12. 12. VENGE P. Monitoring of asthma inflammation by serum measurements of eosinophilic cationic protein (ECP). A new clinical approach to asthma management. Respir Med 1995;89:1-2.
13. 13. REIMERT CM, POULSEN LK, BINDSLEV-JENSEN C, KHARAZMI A, BENDTZEN K. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/ eosinophil derived neurotoxin (EPX/ EDN). J Immunol Methods 1993;166:183-190.
14. 14. HÁKANSSON L, VENGE P. The influence of serum on random migration and chemotaxis of polymorphonuclear leucocytes: methodological evaluation using sera from infection-prone patients and normals. Scand J Immunol 1980;11:271-282.
15. 15. GÄRTNER I. Separation of human eosinophils in density gradients of polyvinyl pyrrolidone-coated silica gel (Percoll). Immunology 1980;40:133-135.
16. 16. HANSEL T, DE VRIES I, IEE T, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105-110.
17. 17. WINQVIST I, OLOFSSON T, OLSSON I. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Immunology 1984;51:1-7.
18. 18. CARLSON M, HÁKANSSON L, KAMPE M, STÅLENHEIM G, PETERSON C, VENGE P. Degranulation of eosinophils from non-atopic patients with asthma is increased during pollen season. J Allergy Clin Immunol 1994;89 no. 1, Pt 1:131-139.
19. 19. WACHTFOGEL YT, KUCICH U, JAMES HL, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-1677.
20. 20. WACHTFOGEL YT, ABRAMS W, KUCICH U, WEINBAUM G, SCHAPIRA M, COLMAN RW. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation. J Clin Invest 1988;81:1310-1316.
21. 21. PRIN L, CHARON J, CAPRON M, et al. Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density. Clin Exp Immunol 1984;57:735-742.
22. 22. FUKUDA T, GLEICH GJ. Heterogeneity of human eosinophils. J Allergy Clin Immunol 1989;83:369-373.
23. 23. PRONK-ADMIRAAL CJ, BARTELS PCM. Effect of clotting temperature and eosinophil concentration on the eosinophil cationic protein concentration in serum. Scand J Clin Invest 1994;55:185-188.